Can we predict dangerous spleen attacks in sickle cell babies?
NCT ID NCT01207037
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study followed 58 babies with sickle cell disease from 3 months to 2 years old to find early clues that might predict a life-threatening spleen complication called acute splenic sequestration. Researchers took blood samples and used special scans to measure spleen size and function. The goal was to identify clinical, biological, and genetic markers that could help doctors spot high-risk children sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which children with sickle cell disease are at highest risk for dangerous spleen problems, allowing earlier monitoring or treatment.
- What could go wrong
- This is a small, observational study that only looks for patterns—it does not test a treatment. The findings may not apply to all children or lead to a proven prediction tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
58 people
The number who actually took part.
- Started
-
Aug 2010
- Finished
-
Nov 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 6 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria : * Children aged 3 to 6 months * homozygous (SS) or S beta° sickle cell disease diagnosed by neonatal screening * With no history of acute splenic sequestration * Signed parental consent * Patient covered by national insurance scheme or CMU Exclusion criteria : * Children with other SCD genotype * Children with congenital anatomical asplenia * Children with previous episode of acute splenic sequestration * Absence of possible follow-up * Simultaneous enrolment in another biomedical research
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anemia; drepanocytic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Necker Hospital
Paris, 75015, France